The stratified win statistics (win ratio, win odds, and net benefit)

The win odds and the net benefit are related directly to each other and indirectly, through ties, to the win ratio. These three win statistics test the same null hypothesis of equal win probabilities between two groups. They provide similar p‐values and powers, because the Z‐values of their statisti...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutical statistics : the journal of the pharmaceutical industry Vol. 22; no. 4; pp. 748 - 756
Main Authors Dong, Gaohong, Hoaglin, David C., Huang, Bo, Cui, Ying, Wang, Duolao, Cheng, Yu, Gamalo‐Siebers, Margaret
Format Journal Article
LanguageEnglish
Published Chichester, UK John Wiley & Sons, Inc 01.07.2023
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The win odds and the net benefit are related directly to each other and indirectly, through ties, to the win ratio. These three win statistics test the same null hypothesis of equal win probabilities between two groups. They provide similar p‐values and powers, because the Z‐values of their statistical tests are approximately equal. Thus, they can complement one another to show the strength of a treatment effect. In this article, we show that the estimated variances of the win statistics are also directly related regardless of ties or indirectly related through ties. Since its introduction in 2018, the stratified win ratio has been applied in designs and analyses of clinical trials, including Phase III and Phase IV studies. This article generalizes the stratified method to the win odds and the net benefit. As a result, the relations of the three win statistics and the approximate equivalence of their statistical tests also hold for the stratified win statistics.
AbstractList The win odds and the net benefit are related directly to each other and indirectly, through ties, to the win ratio. These three win statistics test the same null hypothesis of equal win probabilities between two groups. They provide similar p-values and powers, because the Z-values of their statistical tests are approximately equal. Thus, they can complement one another to show the strength of a treatment effect. In this article, we show that the estimated variances of the win statistics are also directly related regardless of ties or indirectly related through ties. Since its introduction in 2018, the stratified win ratio has been applied in designs and analyses of clinical trials, including Phase III and Phase IV studies. This article generalizes the stratified method to the win odds and the net benefit. As a result, the relations of the three win statistics and the approximate equivalence of their statistical tests also hold for the stratified win statistics.
Abstract The win odds and the net benefit are related directly to each other and indirectly, through ties, to the win ratio. These three win statistics test the same null hypothesis of equal win probabilities between two groups. They provide similar p ‐values and powers, because the Z‐values of their statistical tests are approximately equal. Thus, they can complement one another to show the strength of a treatment effect. In this article, we show that the estimated variances of the win statistics are also directly related regardless of ties or indirectly related through ties. Since its introduction in 2018, the stratified win ratio has been applied in designs and analyses of clinical trials, including Phase III and Phase IV studies. This article generalizes the stratified method to the win odds and the net benefit. As a result, the relations of the three win statistics and the approximate equivalence of their statistical tests also hold for the stratified win statistics.
The win odds and the net benefit are related directly to each other and indirectly, through ties, to the win ratio. These three win statistics test the same null hypothesis of equal win probabilities between two groups. They provide similar p‐values and powers, because the Z‐values of their statistical tests are approximately equal. Thus, they can complement one another to show the strength of a treatment effect. In this article, we show that the estimated variances of the win statistics are also directly related regardless of ties or indirectly related through ties. Since its introduction in 2018, the stratified win ratio has been applied in designs and analyses of clinical trials, including Phase III and Phase IV studies. This article generalizes the stratified method to the win odds and the net benefit. As a result, the relations of the three win statistics and the approximate equivalence of their statistical tests also hold for the stratified win statistics.
Author Dong, Gaohong
Huang, Bo
Wang, Duolao
Cheng, Yu
Hoaglin, David C.
Cui, Ying
Gamalo‐Siebers, Margaret
Author_xml – sequence: 1
  givenname: Gaohong
  orcidid: 0000-0002-9848-1329
  surname: Dong
  fullname: Dong, Gaohong
  email: gaohong.dong@beigene.com
  organization: BeiGene
– sequence: 2
  givenname: David C.
  orcidid: 0000-0003-1336-181X
  surname: Hoaglin
  fullname: Hoaglin, David C.
  organization: UMass Chan Medical School
– sequence: 3
  givenname: Bo
  orcidid: 0000-0002-3088-9328
  surname: Huang
  fullname: Huang, Bo
  organization: Pfizer Inc
– sequence: 4
  givenname: Ying
  surname: Cui
  fullname: Cui, Ying
  organization: Emory University
– sequence: 5
  givenname: Duolao
  surname: Wang
  fullname: Wang, Duolao
  organization: Liverpool School of Tropical Medicine
– sequence: 6
  givenname: Yu
  surname: Cheng
  fullname: Cheng, Yu
  organization: University of Pittsburgh
– sequence: 7
  givenname: Margaret
  orcidid: 0000-0003-2428-3298
  surname: Gamalo‐Siebers
  fullname: Gamalo‐Siebers, Margaret
  organization: Pfizer Inc
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36808217$$D View this record in MEDLINE/PubMed
BookMark eNp1kFtLwzAYhoNM3EHBXyAFbyasM-c0lzKPMFBwXoemSbCjS2fTMvbvbbc5QfDqy8v38PDlHYKeL70F4BLBKYIQ365DPcVYkhMwQIzIGHGEe8c3pH0wDGEJIRKJZGegT3gCE4zEANwvPm0U6iqtc5dbE21y38Y2hTrPQjTucrcsJ7tVaUyYRKk3kbd1pK23Lq9vzsGpS4tgLw5zBD4eHxaz53j--vQyu5vHGaGSxJQLrjNtEi0R5ZwSjTIqpSUGcupSYQUzTGOqnUiMhNwRYRwzUAroUuYgGYHx3ruuyq_Ghlqt8pDZoki9LZugsGj_JzhMaIte_0GXZVP59jqFE8KIYIjgX2FWlSFU1ql1la_SaqsQVF2zqm1Wdc226NVB2OiVNUfwp8oWiPfAJi_s9l-Rentf7ITfcO6Bkg
CitedBy_id crossref_primary_10_1080_19466315_2024_2365629
crossref_primary_10_1002_sim_10140
crossref_primary_10_1016_j_jchf_2023_05_010
crossref_primary_10_1080_10543406_2023_2210658
Cites_doi 10.1080/10543406.2020.1757690
10.1002/pst.2086
10.1016/j.cct.2022.107040
10.1002/pst.1763
10.1002/pst.2251
10.1177/0962280220942558
10.1016/S0140-6736(03)14282-1
10.1007/s43441-022-00420-1
10.1002/sim.8967
10.1080/03610918.2020.1720735
10.1002/sim.3923
10.1038/s41591-021-01659-1
10.1002/(SICI)1097-0258(19990615)18:11<1341::AID-SIM129>3.0.CO;2-7
10.1080/10543406.2020.1757692
10.1080/19466315.2019.1575279
10.1080/10543406.2022.2141769
10.1111/biom.12954
10.1080/10543406.2017.1397007
10.1093/eurheartj/ehr352
10.1198/tast.2010.08121
10.32614/CRAN.package.WINS
10.2307/3001666
10.1016/S0140-6736(21)01203-4
10.1002/sim.9570
ContentType Journal Article
Copyright 2023 John Wiley & Sons Ltd.
2023 John Wiley & Sons, Ltd.
Copyright_xml – notice: 2023 John Wiley & Sons Ltd.
– notice: 2023 John Wiley & Sons, Ltd.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
K9.
7X8
DOI 10.1002/pst.2293
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE
CrossRef

ProQuest Health & Medical Complete (Alumni)
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1539-1612
EndPage 756
ExternalDocumentID 10_1002_pst_2293
36808217
PST2293
Genre shortCommunication
Journal Article
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
123
1L6
1OC
31~
33P
3SF
3WU
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52S
52T
52U
52W
52X
53G
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACPOU
ACSCC
ACXBN
ACXQS
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFZJQ
AHBTC
AHMBA
AITYG
AIURR
AIWBW
AJBDE
AJXKR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AUFTA
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMNLL
BNHUX
BROTX
BRXPI
BY8
CS3
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRSTM
DU5
EBD
EBS
EJD
EMOBN
F00
F01
F04
F5P
FEDTE
G-S
G.N
GNP
GODZA
H.T
H.X
HF~
HGLYW
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRSTM
MSFUL
MSSTM
MXFUL
MXSTM
N04
N05
NF~
O66
O9-
OIG
P2P
P2W
P2X
P4D
PQQKQ
Q.N
Q11
QB0
QRW
R.K
ROL
RWI
RX1
SUPJJ
SV3
UB1
W8V
W99
WBKPD
WIH
WIK
WJL
WOHZO
WQJ
WRC
WXSBR
WYISQ
XBAML
XG1
XV2
ZZTAW
~IA
~WT
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
K9.
7X8
ID FETCH-LOGICAL-c3493-4676bcbd8b9146643b1c499e3d064fa7e75d5b24bf78d906f37df5d0970fa5f03
IEDL.DBID DR2
ISSN 1539-1604
IngestDate Sat Aug 17 01:09:26 EDT 2024
Thu Oct 10 18:53:03 EDT 2024
Wed Oct 16 15:30:59 EDT 2024
Wed Oct 16 00:39:17 EDT 2024
Sat Aug 24 00:57:26 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords win ratio
mantel-Haenszel method
Finkelstein-Schoenfeld test
net benefit
generalized pairwise comparisons
win odds
Language English
License 2023 John Wiley & Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3493-4676bcbd8b9146643b1c499e3d064fa7e75d5b24bf78d906f37df5d0970fa5f03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-2428-3298
0000-0003-1336-181X
0000-0002-3088-9328
0000-0002-9848-1329
PMID 36808217
PQID 2835375132
PQPubID 1036354
PageCount 9
ParticipantIDs proquest_miscellaneous_2778976084
proquest_journals_2835375132
crossref_primary_10_1002_pst_2293
pubmed_primary_36808217
wiley_primary_10_1002_pst_2293_PST2293
PublicationCentury 2000
PublicationDate July/August 2023
2023 Jul-Aug
2023-07-00
20230701
PublicationDateYYYYMMDD 2023-07-01
PublicationDate_xml – month: 07
  year: 2023
  text: July/August 2023
PublicationDecade 2020
PublicationPlace Chichester, UK
PublicationPlace_xml – name: Chichester, UK
– name: England
– name: Macclesfield
PublicationTitle Pharmaceutical statistics : the journal of the pharmaceutical industry
PublicationTitleAlternate Pharm Stat
PublicationYear 2023
Publisher John Wiley & Sons, Inc
Wiley Subscription Services, Inc
Publisher_xml – name: John Wiley & Sons, Inc
– name: Wiley Subscription Services, Inc
References 2018; 28
2010; 64
2021; 20
2023; 22
2019; 75
2022
2020; 30
2010; 29
1999; 18
2022; 51
2023; 124
1954; 10
2022; 56
2022; 41
2020; 12
2021; 397
2021; 30
2012; 33
2016; 15
2021; 40
2022; 28
2003; 362
e_1_2_10_12_1
e_1_2_10_23_1
e_1_2_10_9_1
e_1_2_10_13_1
e_1_2_10_24_1
e_1_2_10_10_1
e_1_2_10_21_1
e_1_2_10_11_1
e_1_2_10_22_1
e_1_2_10_20_1
e_1_2_10_2_1
e_1_2_10_4_1
e_1_2_10_18_1
e_1_2_10_3_1
e_1_2_10_19_1
e_1_2_10_6_1
e_1_2_10_16_1
e_1_2_10_5_1
e_1_2_10_17_1
e_1_2_10_8_1
e_1_2_10_14_1
e_1_2_10_25_1
e_1_2_10_7_1
e_1_2_10_15_1
References_xml – volume: 28
  start-page: 568
  issue: 3
  year: 2022
  end-page: 574
  article-title: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
  publication-title: Nat Med
– volume: 15
  start-page: 430
  issue: 5
  year: 2016
  end-page: 437
  article-title: Is the asymptotic variance estimator of the logarithm of the win ratio under the null hypothesis sound? – A note on the generalized analytic solution to the win ratio by Dong et al. (2016). Supporting information #7 (a post‐publishing note) to Dong et al. (2016)
  publication-title: Pharmaceut Stat
– volume: 33
  start-page: 176
  issue: 2
  year: 2012
  end-page: 182
  article-title: The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities
  publication-title: Eur Heart J
– volume: 51
  start-page: 3645
  issue: 7
  year: 2022
  end-page: 3659
  article-title: Optimal weighted estimation versus Cochran–mantel–Haenszel
  publication-title: Commun Stat – Simulat Comput
– volume: 30
  start-page: 941
  issue: 5
  year: 2020
  end-page: 946
  article-title: The use of the win odds in the design of non‐inferiority clinical trials
  publication-title: J Biopharm Stat
– volume: 40
  start-page: 3367
  issue: 14
  year: 2021
  end-page: 3384
  article-title: Win odds: an adaptation of the win ratio to include ties
  publication-title: Stat Med
– volume: 30
  start-page: 580
  issue: 2
  year: 2021
  end-page: 611
  article-title: Adjusted win ratio with stratification: calculation methods and interpretation
  publication-title: Stat Methods Med Res
– volume: 124
  year: 2023
  article-title: Statistical power considerations in the use of win ratio in cardiovascular outcome trials
  publication-title: Contemp Clin Trials
– volume: 64
  start-page: 121
  issue: 2
  year: 2010
  end-page: 130
  article-title: Rank‐based analyses of stratified experiments: alternatives to the van Elteren test
  publication-title: Am Stat
– volume: 397
  start-page: 2253
  issue: 10291
  year: 2021
  end-page: 2263
  article-title: ACTION coalition COVID‐19 Brazil IV investigators. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID‐19 and elevated D‐dimer concentration (ACTION): an open‐label, multicentre, randomised, controlled trial
  publication-title: Lancet
– volume: 20
  start-page: 440
  issue: 3
  year: 2021
  end-page: 450
  article-title: Adjustingwin statistics for dependent censoring
  publication-title: Pharm Stat
– volume: 18
  start-page: 1341
  year: 1999
  end-page: 1354
  article-title: Combining mortality and longitudinal measures in clinical trials
  publication-title: Stat Med
– volume: 12
  start-page: 99
  issue: 1
  year: 2020
  end-page: 106
  article-title: The win ratio: on interpretation and handling of ties
  publication-title: Statist Biopharm Res
– start-page: 1
  year: 2022
  end-page: 17
  article-title: Evidence synthesis analysis with prioritized benefit outcomes in oncology clinical trials
  publication-title: J Biopharm Stat
– volume: 362
  start-page: 759
  year: 2003
  end-page: 766
  article-title: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM‐overall programme
  publication-title: Lancet
– volume: 29
  start-page: 3245
  issue: 30
  year: 2010
  end-page: 3257
  article-title: Generalized pairwise comparisons of prioritized outcomes in the two‐sample problem
  publication-title: Stat Med
– volume: 56
  start-page: 785
  issue: 5
  year: 2022
  end-page: 794
  article-title: Design and analysis of studies based on hierarchical composite endpoints: insights from the DARE‐19 trial
  publication-title: Ther Innov Regul Sci
– volume: 75
  start-page: 347
  issue: 1
  year: 2019
  end-page: 351
  article-title: On the alternative hypotheses for the win ratio
  publication-title: Biometrics
– volume: 10
  start-page: 101
  year: 1954
  end-page: 129
  article-title: The combination of estimates from different experiments
  publication-title: Biometrics
– volume: 41
  start-page: 5305
  year: 2022
  end-page: 5318
  article-title: Stratified proportional win‐fractions regression analysis
  publication-title: Stat Med
– volume: 30
  start-page: 882
  issue: 5
  year: 2020
  end-page: 899
  article-title: The inverse‐probability‐of‐censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring
  publication-title: J Biopharm Stat
– volume: 28
  start-page: 778
  issue: 4
  year: 2018
  end-page: 796
  article-title: The stratified win ratio
  publication-title: J Biopharm Stat
– volume: 22
  start-page: 20
  issue: 1
  year: 2023
  end-page: 33
  article-title: Win statistics (win ratio, win odds, and net benefit) can complement one another to show the strength of the treatment effect on time‐to‐event outcomes
  publication-title: Pharm Stat
– ident: e_1_2_10_18_1
  doi: 10.1080/10543406.2020.1757690
– ident: e_1_2_10_25_1
  doi: 10.1002/pst.2086
– ident: e_1_2_10_13_1
  doi: 10.1016/j.cct.2022.107040
– ident: e_1_2_10_12_1
  doi: 10.1002/pst.1763
– ident: e_1_2_10_9_1
  doi: 10.1002/pst.2251
– ident: e_1_2_10_22_1
  doi: 10.1177/0962280220942558
– ident: e_1_2_10_17_1
  doi: 10.1016/S0140-6736(03)14282-1
– ident: e_1_2_10_20_1
  doi: 10.1007/s43441-022-00420-1
– ident: e_1_2_10_19_1
  doi: 10.1002/sim.8967
– ident: e_1_2_10_11_1
  doi: 10.1080/03610918.2020.1720735
– ident: e_1_2_10_3_1
  doi: 10.1002/sim.3923
– ident: e_1_2_10_7_1
  doi: 10.1038/s41591-021-01659-1
– ident: e_1_2_10_2_1
  doi: 10.1002/(SICI)1097-0258(19990615)18:11<1341::AID-SIM129>3.0.CO;2-7
– ident: e_1_2_10_24_1
  doi: 10.1080/10543406.2020.1757692
– ident: e_1_2_10_5_1
  doi: 10.1080/19466315.2019.1575279
– ident: e_1_2_10_16_1
  doi: 10.1080/10543406.2022.2141769
– ident: e_1_2_10_14_1
  doi: 10.1111/biom.12954
– ident: e_1_2_10_6_1
  doi: 10.1080/10543406.2017.1397007
– ident: e_1_2_10_4_1
  doi: 10.1093/eurheartj/ehr352
– ident: e_1_2_10_21_1
  doi: 10.1198/tast.2010.08121
– ident: e_1_2_10_10_1
  doi: 10.32614/CRAN.package.WINS
– ident: e_1_2_10_15_1
  doi: 10.2307/3001666
– ident: e_1_2_10_8_1
  doi: 10.1016/S0140-6736(21)01203-4
– ident: e_1_2_10_23_1
  doi: 10.1002/sim.9570
SSID ssj0017895
Score 2.370634
Snippet The win odds and the net benefit are related directly to each other and indirectly, through ties, to the win ratio. These three win statistics test the same...
Abstract The win odds and the net benefit are related directly to each other and indirectly, through ties, to the win ratio. These three win statistics test...
SourceID proquest
crossref
pubmed
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage 748
SubjectTerms Finkelstein‐Schoenfeld test
generalized pairwise comparisons
Humans
mantel–Haenszel method
net benefit
Odds Ratio
Probability
Statistical analysis
win odds
win ratio
Title The stratified win statistics (win ratio, win odds, and net benefit)
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fpst.2293
https://www.ncbi.nlm.nih.gov/pubmed/36808217
https://www.proquest.com/docview/2835375132
https://search.proquest.com/docview/2778976084
Volume 22
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS8MwFA6yJ1-8X-aNCDIU1q1tkiZ9FC-IoAydIPhQmhsMoRuuQ-av96RZN1QE8amUpEmbc8k56TnfQehEMM0TI1WghDutYrkMUiZNECtgDqq5VNQlON_dJzdP9PaZPc-iKl0ujMeHmB-4Ocmo9LUT8FyOuwvQ0NG47MSwWYH6jQh30VyXD3PkqIiLquAKyHMaRElIa9zZMO7WD37diX6Yl1-t1Wq7uV5FL_WL-iiT186klB318Q3D8X9fsoZWZlYoPvdss46WTLGBWj0PYz1t4_4iK2vcxi3cWwBcTzfRJTRjj7drwYLF74MCu8Qkj_mMT919xVjtqmmoNQySFxoXpsQSlKsdlGdb6On6qn9xE8yqMQSK0JQEoFETqaQWMo0cJj2RkQJ3yRANVo3NueFMMxlTabnQaZhYwrVlOkx5aHNmQ7KNGsWwMLsIc2G14EJxQnNw0JhQNDJahSQ3qQIbqImOa8pkIw-6kXl45TiDxcrcYjXRQU2ybCZ248yBxxHOwMOGIebNIDDuL0hemOEE-nDgDZ6EgjbRjif1fBLiCpGAk9ZErYpgv86e9R777rr31477aNkVqveBvgeoUb5NzCGYM6U8qhj3E4aq8Ks
link.rule.ids 315,783,787,1378,27936,27937,46306,46730
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED-67qF7Wbd2H-naVYUSOohT25IsmT6NdSX9JHQp9KFgrC8oA6c0DqX763ey4oR2DMaejJEs2bo76Xey7ncAu5IbkVmlIy39bhUvVZRzZaNUo3IwI5RmPsD5_CIbXLGTa369BAdtLEzgh5hvuHnLaOZrb-B-Q3p_wRp6N6n7Ka5WL-AlWjv1eRsOL-fcUYmQTcoVtOg8SrKYtcyzcbrfPvl0LfoDYD7Fq82Cc7QKN-2rhnMmP_vTWvX1r2csjv_5LW_g9QyIkq9Bc97Ckq3WoDsMTNaPPTJaBGZNeqRLhguO68d1OMRiEih3HYJY8nBbER-bFGifyZ6_b3Sr1xSNjcFGysqQytZE4fzqbusv7-Dq6Pvo2yCaJWSINGU5jXCYM6WVkSpPPC09VYlGj8lSg8DGlcIKbrhKmXJCmjzOHBXGcRPnInYldzF9D8vVuLIfgQjpjBRSC8pK9NG41CyxRse0tLlGGNSBnVY0xV3g3SgCw3Ja4GAVfrA6sNnKrJhZ3qTw_HFUcHSysYl5MdqM_xFSVnY8xToClUNksWQd-BBkPe-E-lwk6Kd1oNtI7K-9F8MfI3_d-NeK27AyGJ2fFWfHF6ef4JXPWx_O_W7Ccn0_tVuIbmr1udHi34Zm9MM
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ra9swED-6Dka_rN2rS58ajLBBnNqWZMkfS9vQ7lHClkJhH4z1glJwQuNQ2r--JytO6Eah7JMxkiVbdyf9Ttb9DuCz5EZkVulIS79bxUsV5VzZKNWoHMwIpZkPcP55np1esG-X_HJ-qtLHwgR-iMWGm7eMZr72Bj4x7mBJGjqZ1v0UF6sX8JJlCHw9IPq1oI5KhGwyrqBB51GSxawlno3Tg_bJx0vRP_jyMVxt1pvBOvxp3zQcM7nuz2rV1_d_kTj-36dswOs5DCWHQW_ewIqt3kJ3GHis73pktAzLmvZIlwyXDNd37-AYi0kg3HUIYcntVUV8ZFIgfSZf_H2jWb2maGwMNlJWhlS2JgpnV3dVf30PF4OT0dFpNE_HEGnKchrhlJoprYxUeeJJ6alKNPpLlhqENa4UVnDDVcqUE9LkceaoMI6bOBexK7mL6QdYrcaV_QhESGekkFpQVqKHxqVmiTU6pqXNNYKgDnxqJVNMAutGEfiV0wIHq_CD1YGdVmTF3O6mhWePo4Kji41NLIrRYvxvkLKy4xnWEagbIosl68BmEPWiE-ozkaCX1oFuI7Aney-Gv0f-uvXcivvwang8KH6cnX_fhjWftD4c-t2B1fpmZncR2tRqr9HhB7Zv83I
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+stratified+win+statistics+%28win+ratio%2C+win+odds%2C+and+net+benefit%29&rft.jtitle=Pharmaceutical+statistics+%3A+the+journal+of+the+pharmaceutical+industry&rft.au=Dong%2C+Gaohong&rft.au=Hoaglin%2C+David+C&rft.au=Huang%2C+Bo&rft.au=Cui%2C+Ying&rft.date=2023-07-01&rft.eissn=1539-1612&rft.volume=22&rft.issue=4&rft.spage=748&rft.epage=756&rft_id=info:doi/10.1002%2Fpst.2293&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1539-1604&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1539-1604&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1539-1604&client=summon